"Breakthrough Weight-Loss Drug by Eli Lilly Surpasses Expectations"

Eli Lilly's experimental drug, retatrutide, has shown the greatest weight loss yet in a mid-stage trial, with patients experiencing a 24.2% reduction in weight. If successful in larger Phase 3 trials, the drug could position Lilly as a leader in the race to provide effective obesity treatments. However, the U.K.'s cost-effectiveness agency has rejected Eli Lilly's Mounjaro as a treatment for type 2 diabetes, citing the need for more evidence on clinical benefits and cost effectiveness. Mounjaro is expected to gain regulatory approval for obesity later this year and is part of a group of medications showing significant weight-loss results.